Evidence map›Paper›PMID 26338463›Full record

ArticleClinical and experimental nephrology2016

Intra-arterial catheter system to repeatedly deliver mesenchymal stem cells in a rat renal failure model.

Yuichi Katsuoka, Hiroki Ohta, Eisuke Fujimoto, Luna Izuhara, Shinya Yokote, Sho Kurihara, Shuichiro Yamanaka, Susumu Tajiri, Tatsuya Chikaraish, Hirotaka J Okano and 1 more

Abstract readEvaluation Study
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Yuichi KatsuokaDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, 105-8461, Japan.
Hiroki OhtaDivision of Regenerative Medicine, Jikei University School of Medicine, Tokyo, Japan.
Eisuke FujimotoDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, 105-8461, Japan.
Luna IzuharaDivision of Regenerative Medicine, Jikei University School of Medicine, Tokyo, Japan.
Shinya YokoteDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, 105-8461, Japan.
Sho KuriharaDivision of Regenerative Medicine, Jikei University School of Medicine, Tokyo, Japan.
Shuichiro YamanakaDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, 105-8461, Japan.
Susumu TajiriDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, 105-8461, Japan.
Tatsuya ChikaraishDepartment of Urology, St. Marianna University School of Medicine, Kawasaki, Japan.
Hirotaka J OkanoDivision of Regenerative Medicine, Jikei University School of Medicine, Tokyo, Japan.
Takashi YokooDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, 105-8461, Japan. tyokoo@jikei.ac.jp.
Jikei University School of Medicine · JPSt. Marianna University School of Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMesenchymal stem cell therapy in renal failure is rarely used because of low rates of cell engraftment after systemic delivery. Repeated intra-arterial cell administration may improve results; however, no current delivery method permits repeated intra-arterial infusions in a rat model. In this study, we developed an intra-arterial delivery system for repeated stem cell infusion via the aorta, catheterizing the left femoral artery to the suprarenal aorta under fluoroscopic guidance in rats with adenosine-induced renal failure.

methodsFirst, we compared our intra-arterial catheter system (C group, n = 3) with tail vein injection (V group, n = 3) for engraftment efficacy, using mesenchymal stem cells from luciferase transgenic rats. Rats were infused with the cells and euthanized the following day; we performed cell-tracking experiments using a bioluminescence imaging system to assess the distribution of the infused cells. Second, we assessed the safety of the system over a 30-day period in a second group of six rats receiving infusions every 7 days.

resultsCells infused through our delivery system efficiently engrafted into the kidney, compared with peripheral venous infusion. In five of the six rats in the safety study, the delivery system remained patent for at least 9 days (range, 9-24 days). Complications became evident only after 10 days.

conclusionOur intra-arterial catheter system was effective in delivering cells to the kidney and permitted repeated injection of cells.

Indexed as

AnimalsCatheters, IndwellingDisease Models, AnimalMesenchymal Stem Cell TransplantationRats, Inbred LewRenal InsufficiencyIntra-arterialMesenchymal stem cell therapyRat model

Identifiers

PMID26338463
OpenAlexW2237146741

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.